Pacific Edge permanently on cusp of success - or oblivion
The cancer diagnostics company has been undercapitalised from the get-go.
A wise investor once laid out to your columnist the Law of Three when examining the prospects of startup businesses. Roughly stated:
“Assume the new concern will take three times as long and spend three times as much to get past breakeven compared with the promoter’s forecasts, no matter
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Pacific Edge permanently on cusp of success - or oblivion
Shoeshine,Columns,
79753